Rajni Mehta, MPH
Associate Director Rapid Case Ascertainment Cancer CenterDownloadHi-Res Photo
Cards
Additional Titles
Director, Rapid Case Ascertainment Shared Resource
Contact Info
About
Copy Link
Titles
Associate Director Rapid Case Ascertainment Cancer Center
Director, Rapid Case Ascertainment Shared Resource
Biography
Rajni Mehta is the Director of the Rapid Case Ascertainment (RCA) Shared Resource Core of the Yale Cancer Center, a position she has held since 2000. Ms. Mehta has managed over 30 cancer related studies in Connecticut. These include studies that require rapid case identification of newly diagnosed cancer cases for prospective epidemiologic studies. She also works with other cohorts of cancer studies that involve retrospective data collection at hospitals. She served on the Yale School of Medicine Human Investigation Committee (IRB) from 2002 to 2010. Her experience with study implementation helps investigators accomplish their goals, and provides advice and assistance to investigators not only for studies that are already funded but also for studies that are in the planning stages. In addition, she is working on a large Hepatocellular carcinoma (HCC) cohort study at the Veteran’s Administration (VA) examining the complications of cirrhosis, specifically HCC and its effects on patient outcomes and healthcare costs. Ms. Mehta was a member of the VA Cooperative Studies Program (CSP) Human Rights Committee (HRC) for 18 years conducting study reviews and site visits to determine if human rights of subjects are being adequately protected and to ensure that informed consent procedures are conducted appropriately.
Last Updated on February 06, 2024.
Departments & Organizations
Education & Training
- MPH
- Yale University, Epidemiology (1998)
Research
Copy Link
Overview
Public Health Interests
Cancer
ORCID
0000-0002-3378-5583
Research at a Glance
Yale Co-Authors
Frequent collaborators of Rajni Mehta's published research.
Publications Timeline
A big-picture view of Rajni Mehta's research output by year.
Tamar Taddei, MD
Cary P Gross, MD
Catherine Mezzacappa, MD, MPH, PhD
Guadalupe Garcia-Tsao, MD, FRCP
Ifeyinwa Onyiuke, MBBS
Shi-Yi Wang, MD, PhD
13Publications
799Citations
Publications
2025
Practice changing RCT design and rationale: Abbreviated MRI plus AFP vs. ultrasound plus AFP for HCC surveillance in cirrhosis (PREMIUM study)
Ioannou G, Taddei T, Planeta B, Huang G, Weiss N, Morgan T, Dominitz J, Abou-Alfa G, Bashir M, Beheshti M, Singal A, Moylan C, Boland R, Buchwalder L, Mehta R, Hoisington K, V. N, Rogal S, Kaplan D, Benhammou J, Su G, McDonald L, Dani G, Dunn D, Chang S, Onyiuke I, Sharma A, Kyriakides T, Su G, Lane A, Baffy G, Lee T, Hunt K, Davitkov P, Hernaez R, Morgan T, Pisegna J, Patel A, Said A, Albanese A, Mannon P, Cheung R, Kaplan D, Patton H, Barnard-Giustini A, Kulkarni P, Jakab S, Azar S, Rau T, Jati A, Hunt K, Kang P, Hanif M, Borghei P, Walsworth M, Swietlik J, Abedin S, Rabe T, Chang S, Khan M, Vahdat N, Rago J, Kumar P, Onyiuke I. Practice changing RCT design and rationale: Abbreviated MRI plus AFP vs. ultrasound plus AFP for HCC surveillance in cirrhosis (PREMIUM study). JHEP Reports 2025, 8: 101666. PMID: 41624484, PMCID: PMC12857331, DOI: 10.1016/j.jhepr.2025.101666.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetric
2022
Cancer tracking system improves timeliness of liver cancer care at a Veterans Hospital: A comparison of cohorts before and after implementation of an automated care coordination tool
Zhang Y, Mezzacappa C, Shen L, Ivatorov A, Petukhova-Greenstein A, Mehta R, Deng Y, Levin W, Steinhardt S, Connery D, Pineau M, Onyiuke I, Taylor C, Rose M, Taddei T. Cancer tracking system improves timeliness of liver cancer care at a Veterans Hospital: A comparison of cohorts before and after implementation of an automated care coordination tool. PLOS Digital Health 2022, 1: e0000080. PMID: 36812575, PMCID: PMC9931271, DOI: 10.1371/journal.pdig.0000080.Peer-Reviewed Original ResearchCitationsAltmetric
2021
SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation
Kaplan D, Mehta R, Garcia-Tsao G, Albrecht J, Aytaman A, Baffy G, Bajaj J, Hernaez R, Hunt K, Ioannou G, Johnson K, Kanwal F, Lee T, Monto A, Pandya P, Schaubel D, Taddei T. SACRED: Effect of simvastatin on hepatic decompensation and death in subjects with high-risk compensated cirrhosis: Statins and Cirrhosis: Reducing Events of Decompensation. Contemporary Clinical Trials 2021, 104: 106367. PMID: 33771685, PMCID: PMC8422958, DOI: 10.1016/j.cct.2021.106367.Peer-Reviewed Original ResearchCitationsAltmetric
2018
Implementation of a Population-Based Cirrhosis Identification and Management System
Kanwal F, Mapaskhi S, Smith D, Taddei T, Hussain K, Madu S, Duong N, White D, Cao Y, Mehta R, El-Serag H, Asch S, Midboe A. Implementation of a Population-Based Cirrhosis Identification and Management System. Clinical Gastroenterology And Hepatology 2018, 16: 1182-1186.e2. PMID: 29803805, PMCID: PMC7185902, DOI: 10.1016/j.cgh.2018.01.041.Peer-Reviewed Original ResearchCitationsAltmetricTransarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching
Kaplan DE, Mehta R, D'Addeo K, Gade TP, Taddei TH. Transarterial Chemoembolization within First 3 Months of Sorafenib Initiation Improves Overall Survival in Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study with Propensity Matching. Journal Of Vascular And Interventional Radiology 2018, 29: 540-549.e4. PMID: 29477619, PMCID: PMC6104514, DOI: 10.1016/j.jvir.2017.11.033.Peer-Reviewed Original ResearchCitationsSorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma
Kaplan DE, Mehta R, D’Addeo K, Valderrama A, Taddei TH. Sorafenib prescribed by gastroenterologists and hepatologists for hepatocellular carcinoma. Medicine 2018, 97: e9757. PMID: 29369224, PMCID: PMC5794408, DOI: 10.1097/md.0000000000009757.Peer-Reviewed Original ResearchCitationsAltmetric
2017
Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study
Reiss KA, Yu S, Mamtani R, Mehta R, D'Addeo K, Wileyto EP, Taddei TH, Kaplan DE. Starting Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma: A Retrospective, Multi-Institutional Study. Journal Of Clinical Oncology 2017, 35: jco.2017.73.824. PMID: 28872925, PMCID: PMC5662845, DOI: 10.1200/jco.2017.73.8245.Peer-Reviewed Original ResearchCitationsAltmetricHealthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United States
Kaplan DE, Chapko MK, Mehta R, Dai F, Skanderson M, Aytaman A, Baytarian M, D’Addeo K, Fox R, Hunt K, Pocha C, Valderrama A, Taddei TH, Group V. Healthcare Costs Related to Treatment of Hepatocellular Carcinoma Among Veterans With Cirrhosis in the United States. Clinical Gastroenterology And Hepatology 2017, 16: 106-114.e5. PMID: 28756056, PMCID: PMC5735018, DOI: 10.1016/j.cgh.2017.07.024.Peer-Reviewed Original ResearchCitationsAltmetricRacial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study.
Davis BA, Aminawung JA, Abu-Khalaf MM, Evans SB, Su K, Mehta R, Wang SY, Gross CP. Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study. Journal Of The National Comprehensive Cancer Network 2017, 15: 346-354. PMID: 28275035, DOI: 10.6004/jnccn.2017.0034.Peer-Reviewed Original ResearchCitationsAltmetricMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorBreast NeoplasmsConnecticutFemaleGene Expression ProfilingGenetic TestingHealth Services AccessibilityHealthcare DisparitiesHumansLymphatic MetastasisMiddle AgedNeoplasm GradingNeoplasm StagingOdds RatioPatient Outcome AssessmentPopulation SurveillanceRegistriesRetrospective StudiesSocioeconomic FactorsYoung AdultAssociation of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality
Serper M, Taddei TH, Mehta R, D’Addeo K, Dai F, Aytaman A, Baytarian M, Fox R, Hunt K, Goldberg DS, Valderrama A, Kaplan DE, Group V. Association of Provider Specialty and Multidisciplinary Care With Hepatocellular Carcinoma Treatment and Mortality. Gastroenterology 2017, 152: 1954-1964. PMID: 28283421, PMCID: PMC5664153, DOI: 10.1053/j.gastro.2017.02.040.Peer-Reviewed Original ResearchCitationsAltmetricMeSH KeywordsAgedCarcinoma, HepatocellularChi-Square DistributionDelivery of Health Care, IntegratedFemaleGastroenterologistsHumansKaplan-Meier EstimateLiver NeoplasmsLogistic ModelsMaleMiddle AgedMultivariate AnalysisOdds RatioOncologistsPatient Care TeamPractice Patterns, Physicians'Proportional Hazards ModelsRetrospective StudiesRisk AssessmentRisk FactorsSpecializationSurgeonsTime FactorsTreatment OutcomeUnited StatesUnited States Department of Veterans Affairs
Clinical Trials
Current Trials
Determining Mechanisms of Sensitivity and Resistance to Anti-Cancer Therapy for Advanced Lung Cancer
IRB ID1603017333RoleSub InvestigatorPrimary Completion Date06/16/2036Recruiting Participants
News & Links
Copy Link
Media
Rapid Case Ascertainment Shared Resource
Working as an agent of the Connecticut Tumor Registry, the Rapid Case Ascertainment (RCA) Shared Resource facilitates population-based studies of cancer for YCC investigators as well as outside investigators.
Contact
Rajni Mehta, MPH, Director
News
Get In Touch
Copy Link
Contacts
Email